Oncolytics Biotech, Inc. Q3 FY2023 earnings call

• Oncolytics has made substantial progress, with highlights including data from the GOBLET study showing pela combined with atezolizumab meeting Simon 2-stage success criteria in pancreatic and third-line colorectal cancer. • Pela's combination with chemotherapy and checkpoint inhibitors shows potential as an immune therapy backbone, with well-tolerated treatment and expansion of tumor-infiltrating lymphocytes correlated with response. • Transition to a late-stage company with the upcoming start of the Phase III Precision Promise study in pancreatic cancer and a $5 million grant from PanCAN for a new Phase II combination study in pancreatic cancer. • Clinical program updates include progress on the BRACELET-1 breast cancer study, translational data from the AWARE-1 study presented at SITC, and progress on the GOBLET anal cancer cohort.

No detailed product segment financial performance with revenue contributions provided in the transcript.

• Expect to report survival data for the BRACELET-1 study in patients with HR+/HER2- breast cancer in 2024. • Plan to start the Phase III Precision Promise study in pancreatic cancer in the first half of 2024. • Intend to initiate a new arm in the GOBLET study evaluating pela in combination with modified FOLFIRINOX with or without atezolizumab in patients with early-stage pancreatic cancer in the first half of 2024. • Expect to provide an update on the fourth cohort from the GOBLET trial in patients with anal cancer by the end of 2023.

• Factors such as results of current or pending clinical trials, risks associated with intellectual property protection, financial uncertainties, and actions by regulatory agencies may materially affect actual results. • Uncertainty in partnering timings and potential toxicities with new drug combinations pose risks.

Q: About BRACELET-1 data and GOBLET anal data, partnership discussions.

A: Matt Coffey and Thomas Heineman responded, discussing BRACELET-1 survival data tracking, GOBLET anal data interim results, and partnership goals for large biopharma with global oncology focus.

Q: About PanCAN study dosing.

A: Thomas Heineman responded, noting the Precision Promise study protocol and the GOBLET study's option to treat past progression with modified FOLFIRINOX.

Q: About pancreatic study comparators and biomarkers.

A: Matt Coffey and Thomas Heineman responded, discussing NAPOLI study comparisons, TIL expansion as a biomarker, and other biomarker work like CEACAM6 levels.

Q: About breast cancer checkpoint inhibitor combination.

A: Matt Coffey responded, discussing the synergy of pela with certain checkpoint inhibitors like atezolizumab and the issues with avelumab's Fc portion, and the importance of studying other checkpoint combinations for breast cancer life cycle management.